Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 01 March 2017 | By Michael Mezher
The US Food and Drug Administration (FDA) in late February warned Fosun Pharmaceutical subsidiary, the formerly Chinese state-owned Chongqing Pharmaceutical Research Institute (CPRI), over data integrity issues.
The warning letter comes after a four-day inspection of CPRI's active pharmaceutical ingredient (API) and contract research and manufacturing facility in Chongqing, China last May.
During the inspection, FDA says it found evidence the company was habitually deleting failed test results in order to meet batch release specifications.
According to FDA, audit trails from CPRI's laboratory equipment revealed that the company had deleted sequences from their high performance liquid chromatography (HPLC) and gas chromatography (GC) analyses.
"The audit trail showed that the final standard injection was permanently deleted from the instrument's computer. Your analyst told our investigator that it is laboratory practice to perform more injections than are required by the procedure, and then delete any undesirable results to ensure passing sustainability tests," FDA writes.
In light of this practice, FDA says the company's quality system does not adequately ensure the accuracy or integrity of the data demonstrating the safety, effectiveness or quality of the drugs manufactured at CPRI's facility.
As a result, the agency is calling on the company to conduct an investigation into its data records and reporting practices and perform a risk assessment on the potential impact on its products.
Data integrity has been a growing area of focus for FDA. In recent years an increasing number of warning letters and Form 483s issued to establishments, primarily in China and India, include citations for data integrity issues. In April 2016, FDA released a draft guidance detailing its expectations and best practices for complying with data integrity requirements.
FDA
Tags: Data Integrity
Regulatory Focus newsletters
All the biggest regulatory news and happenings.